Advances in treatment of peritoneal metastasis from colorectal cancer
10.3969/j.issn.1000-8179.2020.03.251
- VernacularTitle: 结直肠癌腹膜转移治疗的临床研究进展
- Author:
Guoxiang CAI
1
Author Information
1. Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University
- Publication Type:Journal Article
- Keywords:
Colorectal cancer (CRC);
Cytoreductive surgery;
Hyperthermic interaperitoneal chemotherapy (HIPEC);
Peritoneal metastasis (PM);
Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
- From:
Chinese Journal of Clinical Oncology
2020;47(3):118-122
- CountryChina
- Language:Chinese
-
Abstract:
Peritoneum is the third common metastatic site of colorectal cancer (CRC) following liver and lung. CRC peritoneal metastasis (PM) has been reckoned as an advanced disease with dismal prognosis. With the development of modern chemotherapeutic modalities, the prognosis of patients with metastatic CRC has been dramatically improved, yet patients with CRC PM achieved few survival benefits. It is the emergence and combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy that prolong the survival of PM cases. What's more, novel treatments, pressurized intraperitoneal aerosol chemotherapy, and intraperitoneal MOC31PE immunotoxin treatment, for instance, have been under investigation and preliminary results are promising. We aim to comprehensively review the literature focusing on the clinical treatment of PM.
